Novel Use of Regorafenib in Combination with Nivolumab in Patients with Recurrent or Refractory Osteosarcoma

Pediatric Osteosarcoma
Fariba Navid, MD
Children's Hospital Los Angeles


Dr. Navid and team are examining if the addition of an immunotherapy drug (nivolumab) increases the effectiveness of a chemotherapy regimen (regorafenib) for patients age 5 years or older diagnosed with recurrent or refractory osteosarcoma. Patients at SARC subsites throughout the US will randomly be placed into 2 groups: group 1 will receive the standard chemotherapy regimen, while group 2 will have the immunotherapy drug added to their treatment. This will allow Dr. Navid’s team to determine if the addition of the immunotherapy led to better patient outcomes compared to chemotherapy alone. If successful, this trial will create a new treatment option for a cancer type that has had no improvement in patient outcomes for over 30 years.